Stay up to date
Latest news
2023 National Immunisation Program influenza vaccination – Early advice for vaccination providers
Vaccination against influenza (flu) continues to be important this year. Vaccination is our best defence against flu viruses.
Release of the Australian Government's response to the Review of COVID-19 Vaccine and Treatment Purchasing and Procurement
The Australian Government has responded to the Halton review into COVID-19 vaccine and treatment procurement.
ATAGI recommendations on use of the Moderna bivalent (Original/Omicron BA.4/5) COVID-19 vaccine
Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) on the use of the Moderna bivalent (Original/Omicron BA.4/5) COVID-19 vaccine.
ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.4/5) COVID-19 vaccine
Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) on the use of the Pfizer bivalent (Original/Omicron BA.4/5) COVID-19 vaccine.
Changes to HPV vaccine dose schedule for young Australians
From 6 February 2023 the human papillomavirus (HPV) vaccine schedule will become a single dose schedule. Catch-up under the National Immunisation Program (NIP) will also be extended to all Australians 25 years and under.
Expressions of interest to join the Australian Technical Advisory Group on Immunisation
We are seeking expressions of interest to fill 7 vacancies on the Australian Technical Advisory Group on Immunisation (ATAGI), commencing 1 July 2023. Consider applying if you are a clinical professional, researcher, service delivery expert or consumer expert.
Mandatory reporting of Japanese encephalitis virus vaccines to the Australian Immunisation Register began on 21 December 2022
From 21 December 2022, vaccination providers must report all Japanese encephalitis virus (JEV) vaccines administered to the Australian Immunisation Register (AIR).
ATAGI recommendations for a booster dose of the paediatric Pfizer COVID-19 vaccine in children aged 5 to 11 years
Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) on Pfizer booster doses for children aged 5 to 11 years.
ATAGI recommend the COVID-19 vaccination for some children aged 6 months to under 5 years
Australia’s immunisation experts, the Australian Technical Advisory Group on Immunisation, recommend COVID-19 vaccination for some children aged 6 months to under 5 years who have an increased risk of getting very sick from COVID-19. The COVID-19 vaccination will help reduce this risk.
ATAGI update following COVID-19 meeting – 7 September 2022
An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their meeting on 7 September 2022. ATAGI are now meeting every fortnight on COVID-19 related issues.
ATAGI statement on use of the Moderna bivalent Original/Omicron vaccine
A statement from the Australian Technical Advisory Group on Immunisation (ATAGI) regarding COVID-19 Moderna Spikevax Bivalent Original/Omicron BA.1 vaccine.
AHPPC Statement – reduced isolation period for COVID-19 cases
The Australian Health Protection Principal Committee (AHPPC) notes the need for a proportionate approach to isolation for those with COVID‑19 infections at this stage of the pandemic.
ATAGI update following weekly COVID-19 meeting – 31 August 2022
An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 31 August 2022.
National Cabinet Statement on COVID-19 settings
The following statement was released following the conclusion of National Cabinet on Wednesday 31 August 2022.
ATAGI update following weekly COVID-19 meeting – 24 August 2022
An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 24 August 2022.
Novavax vaccine for adolescents aged 12–17 years
Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) on the use of the Novavax vaccine for adolescents aged 12-17 years.
ATAGI recommends COVID-19 vaccine use in some children aged 6 months to 4 years
From 5 September 2022, the Australian Technical Advisory Group on Immunisation (ATAGI) recommends COVID-19 vaccination for children aged 6 months to 4 years who are severely immunocompromised, have a disability, or have complex and/or multiple health conditions.
ATAGI update following weekly COVID-19 meeting – 3 August 2022
An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 3 August 2022
ATAGI recommendations on COVID-19 vaccine use in children aged 6 months to <5 years
Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) COVID-19 vaccine use in children.
ATAGI update following weekly COVID-19 meeting – 27 July 2022
An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 27 July 2022.
ATAGI update following weekly COVID-19 meeting – 20 July 2022
An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 20 July 2022.
Chief Medical Officer Professor Paul Kelly's interview on ABC News Breakfast on 20 July 2022
Read the transcript of Chief Medical Officer Professor Paul Kelly's interview on ABC News Breakfast on 20 July 2022.
Chief Medical Officer Professor Paul Kelly's interview on Today Show on 20 July 2022
Read the transcript of Chief Medical Officer Professor Paul Kelly's interview with Karl Stefanovic and Allison Langdon on Today Show on 20 July 2022.
Chief Medical Officer Professor Paul Kelly's interview on Sunrise on 20 July 2022
Read the transcript of Chief Medical Officer Professor Paul Kelly's interview with Sunrise on 20 July 2022
Press conference with Chief Medical Officer Paul Kelly and Minister Mark Butler
Read the transcript of the press conference with Chief Medical Officer Paul Kelly and Minister Mark Butler on Tuesday 19 July 2022.
Date last updated: